CD274 and hepatocellular carcinoma: While PD-L1 immunoreactivity has been associated with improved outcomes in colorectal and lung cancers [5,6], it correlates with reduced survival in gastric cancer [7], hepatocellular carcinoma [8], bladder cancer [9], and oesophageal carcinoma [10].